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Genomic profiling of human cancers has identified recurrent somatic mutations of HER2 (encoded by ERBB2) and HER3 (ERBB3), typically occurring in the absence of gene amplification [1] [2] [3] . Mutations in HER2 are clustered in the extracellular, transmembrane and kinase domains. Unlike other mutant oncogenes, such as BRAF or KRAS, no single mutant allele predominates and the precise distribution of mutations varies by tumour type 4 . By contrast, HER3 mutations cluster primarily in the extracellular domain and to a lesser extent in the kinase domain. Although HER2 and HER3 mutations are found in a wide variety of cancers, their overall prevalence does not exceed 10% in any individual tumour type, and the rate is more typically less than 5% for HER2 and less than 1% for HER3.
Biological modelling has yielded conflicting findings as to the functional consequences of HER2 and HER3 mutations. Substantial data suggest that a subset of these mutations induce ligand-independent constitutive HER2 receptor signalling and promote oncogenesis [5] [6] [7] . The mechanism of these oncogenic effects seems to differ by variant, with some causing enhanced HER2 kinase activity and others causing receptor dimerization 5, 8 . Mutations in HER3, which in its wild-type configuration has impaired kinase function, seem to rely on wild-type HER2 to exert its oncogenic effects 7 . Most preclinical data that explore the functional consequences of HER2 and HER3 mutations have been generated using engineered models that overexpress the mutation, and thus the results may be confounded by the known oncogenic effects of HER2 overexpression. Further enforcing the potential importance of this confounding variable, models of HER2 mutation generated by gene-editing techniques have failed to demonstrate a malignant phenotype in the absence of mutations in other oncogenes such as PIK3CA 9 .
Given the considerable diversity of HER2 and HER3 mutations, as well as the challenge of generating preclinical models that recreate their true biology in human cancers, we sought to define the therapeutic importance of HER2 and HER3 mutations by conducting SUMMIT-a global, multicentre, multi-histology basket trial in patients with tumours that contain these mutations (Extended Data Fig. 1 ). Patients were treated with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, which potently inhibits the growth of HER2-mutant tumours in preclinical models 5 . Tumour tissue and plasma were collected to facilitate the detailed genomic characterization of patients. Here we present the results of this study, with a focus on the insights it provides into the biological and therapeutic importance of HER2 and HER3 mutations in patients with cancer.
Patient and mutation characteristics
Baseline patient demographics are shown in Table 1 and Extended Data Table 1 . In total, 141 patients (125 with HER2-mutant tumours, 16 with HER3-mutant tumours) received neratinib treatment. These patients were diagnosed with 1 out of 21 unique cancer types, the most common being breast, lung, bladder and colorectal cancer (61% of patients treated). As has been seen in other basket studies 10, 11 , we identified and enrolled several orphan tumour types including cancers of the biliary tract, salivary gland, small bowel and vagina, as well as extramammary Paget's disease (in aggregate, 13% of all patients). Patients tended to be heavily pretreated with approximately half having received at least three previous lines of systemic therapy.
Enrolled patients had 31 unique HER2 and 11 unique HER3 mutations (Extended Data Fig. 2 ). The most frequent HER2 mutations Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology. were S310, L755, Y772_A775dup and V777 alleles. The HER2 kinase domain was most commonly mutated (66%), followed by the extracellular (26%) and transmembrane/juxtamembrane (8%) domains. The anticipated relationships between the mutated HER2 domain and tumour type were observed, with extracellular domain mutations predominant in bladder cancer, kinase domain missense mutations in breast and colon cancer, and kinase domain insertions in lung cancer 4 . Missense mutations were the most common class of genomic alteration (74%), followed by in-frame insertions (22%), the latter exclusively affecting the kinase domain. Two tumours contained HER2 insertions/ deletions and one an in-frame kinase domain-retaining fusion (GRB7-ERBB2) 12, 13 . HER3 mutations were all missense variants and clustered in the extracellular furin-like and receptor domains. In total, 87% (109 out of 125) of HER2 and 75% (12 out of 16) of HER3 mutations were at positions now known to be mutational hotspots 4 . This pattern of HER2 and HER3 mutations was comparable to the spectrum of nontruncating HER2 and HER3 mutations observed in previously published genomic landscape studies, including The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) 4 , although HER2 V777L and Y772_A755dup were more common in our study cohort (13.6% versus 5.3% and 12.0% versus 2.7%, respectively; Extended Data Fig. 3 ).
Article reSeArcH

Treatment outcomes
When stratified by tumour type, we observed responses to neratinib in patients with HER2-mutant breast, non-small-cell lung, cervical, biliary and salivary cancers, which led to expanded enrolment in several of these tumour types ( Fig. 1a , Extended Data Table 1 ). Neratinib exhibited the greatest degree of activity in patients with breast cancer (n = 25 total, objective response rate at week 8 (ORR 8 ) 32%, 95% confidence interval 15-54%), with responses observed in patients with missense mutations involving the extracellular and kinase domains, as well as insertions in the kinase domain. All patients with breast cancer were classified as HER2-negative (non-amplified) at the time of enrolment as per established guidelines 14 . Responses were observed in both oestrogen receptor-positive (30%, 6 out of 20) and -negative (40%, 2 out of 5) tumours. Overall, these breast cancer data are generally consistent with a previous report 15 . In patients with lung cancer (n = 26), in which insertions in exon 20 predominate, we observed only one objective response. Of note, HER2 exon 20 insertions are paralogous of EGFR exon 20 insertions, which are resistant to first-and second-generation EGFR tyrosine kinase inhibitors 16 . Notably, the only patient with lung cancer to achieve a response evaluation criteria in solid tumours (RECIST) response had a kinase domain missense mutation (L755S). Despite the low response rate, the median progression-free survival in recurrent lung cancer was 5.5 months, with 6 patients remaining on therapy for more than 1 year, which compares favourably to second-line chemotherapy and immune checkpoint inhibitors 17 , suggesting that neratinib may have a positive effect on the natural history of this disease. Responses were also observed in biliary and cervical cancers, and enrolment is ongoing in these cohorts to define this activity better. No responses were observed in bladder cancer (n = 16) or colorectal cancer (n = 12), suggesting lineage-dependent resistance to single-agent pan-HER kinase inhibition in these tumour types. In summary, among the HER2-mutant cohorts, breast cancer met the primary endpoint for efficacy, whereas lung, colorectal and bladder cancers did not. For the remaining tumour-specific cohorts, enrolment is continuing and they have therefore not undergone final efficacy analysis. Despite preclinical data to suggest that HER3 mutations can be oncogenic drivers, no responses to neratinib were observed in patients with HER3-mutant tumours.
When stratified by mutant allele, responses were observed in patients with tumours containing HER2 S310, L755, V777, G778_P780dup and Y772_A775dup mutations ( Fig. 1b ). Among patients with HER2 kinase domain hotspot missense mutations (n = 42), responses were noted in four unique tumour types (breast, biliary, lung and salivary gland). By allele, we observed responses in several kinase domain mutants including L755S (n = 4), V777L (n = 4) and L869R (n = 1). In patients with HER2 hotspot extracellular domain mutations (S310, n = 30), responses were observed in breast, cervical and biliary cancers (n = 1 for each), but not in bladder cancer, the cancer type in which these mutations predominate. Similarly, in patients with HER2 exon 20 insertions (n = 28), responses were observed in two patients with breast cancer, but none were seen in patients with lung cancer, in which this class of alteration is most common. In exon 20 insertions, preservation of glycine at the 770 position, which seems to facilitate binding of covalent HER kinase inhibitors such as neratinib, did not predict for response as previously suggested by preclinical modelling 18 (Extended Data Fig. 4) . Similarly, the number of amino acids involved in the insertion did not seem to predict outcome, with responses observed in patients with both 3 (G788_P780dup) and 4 (Y722_A755dup) amino acid insertions. Finally, among the 15 patients with HER2 mutations not known to be hotspots, only one responded to neratinib. Notably, this response occurred in a patient with breast cancer and a complex insertion/ substitution (L755_E757delinsS), which, to our knowledge, has not been observed previously. Although this case illustrates that the tumours of some patients may be addicted to truly private oncogenic drivers (those arising in only a single patient), it is also noteworthy that this insertion occurs in a domain that is the target of recurrent insertions. The absence of clinical activity in the remaining 14 patients with cancers with non-hotspot mutations suggests that, although the recurrence of a mutation in HER2 is insufficient to define it as sensitizing to a HER2 kinase inhibitor, the absence of recurrence (that is, mutations that do not occur at hotspot positions) provides circumstantial evidence that the alteration is unlikely to be a driver.
Although the overall numbers of patients in each subgroup preclude formal statistical comparison, integrating efficacy, mutational and lineage data, we observed that clinical benefit from neratinib therapy appeared to vary as a function of both mutational and disease context ( Fig. 2) . In tumour types sensitive to neratinib therapy, such as breast, biliary and cervical cancers, responses were collectively observed across all types and classes of HER2 mutations. By contrast, in lung cancer, a tumour type that exhibits modest sensitivity to neratinib, response was limited to a patient with a HER2 kinase domain missense mutation-a class of mutation with greater in vitro sensitivity to neratinib 5 . Finally, in tumour types with intrinsic lineage-based resistance to neratinib, such as bladder and colorectal cancers, responses were not observed regardless of the HER2 mutation, type or class.
Safety
All patients received neratinib with mandatory anti-diarrhoeal prophylaxis. With this regimen, the rate of grade 3 diarrhoea was 22% (Extended Data Table 2 ), consistent with previous experience 19 . Among patients who developed grade 3 diarrhoea, the median time to onset was 10 days and the median duration of the diarrhoea episode was 2 days. Patients were typically managed with dose interruption and reduction, with only 2.8% permanently discontinuing therapy owing to diarrhoea. The remainder of adverse events were predominantly low-grade.
Central confirmation of HER2 and HER3 mutations
There is active debate within the cancer research community as to whether central confirmation of mutational status before study entry is optimal for determining trial eligibility for precision medicine studies. To define the reproducibility of local mutational testing, DNA from archival formalin-fixed paraffin-embedded tumour and plasma samples were re-sequenced (see Methods). A total of 33 patients (26 HER2-mutant, 7 HER3-mutant) were excluded from this concordance analysis because the local test used was the same as the central tumour assay being evaluated. Of the remaining 99 patients with HER2 mutations, adequate material for tumour genomic testing was unobtainable for 26 patients. Overall, concordance in the remaining patients based on central tumour and/or plasma sequencing was 95% (69 out of 73), with 38 patients assessed by tissue and plasma, 14 by tissue alone, and 21 by plasma alone. Central testing identified one locally reported mutation (V773M) as a germline polymorphism and this patient, with renal cell carcinoma, had progressive disease at first scan. Central testing in the four cases in which the HER2 mutation could not be confirmed passed all quality-control metrics, but in two patients the testing was performed on material collected at least three years after the tissue used for local testing, raising the possibility that tumour heterogeneity was involved in the discordance. None of the patients with discordant HER2 results responded to neratinib, and their median progression-free survival was only 43 days (range: 5-58 days). Among the 9 patients eligible for concordance testing with HER3 mutations, tumour tissue was available for central sequencing in 8 patients, and overall concordance was 75% (6 out of 8).
Genomic modifiers of response
Given the variability of treatment response, even among patients with the same tumour lineage and HER2-mutant allele, we sought to identify other genomic modifiers of response through broader genomic characterization of tumour-derived DNA (see Methods). First, we Article reSeArcH explored the relationship between ERBB2 amplification and outcome, as this is a well-established predictor of response to HER2-targeted therapies in patients lacking HER2 mutations. In total, 17% of patients (15 out of 86) had concurrent HER2 mutations and gene amplification. Amplifications preferentially targeted the mutant allele locus (86%, 12 out of 14 evaluable). Using a dichotomous definition of clinical benefit (stable disease or partial response lasting at least 24 weeks), ERBB2 amplification did not correlate with outcome (P = 0.50; Fig. 3 ), suggesting that in the presence of HER2 mutations, amplification may not confer additional sensitivity to irreversible HER kinase inhibitors. We also explored the relationship of ERBB2 mutation clonality on outcomes. In the 74 patients with adequate material to allow definitive assessment of ERBB2 mutant clonality, the mutation was clonal in 95% (70 out of 74; Extended Data Fig. 5a ). None of four patients with a subclonal ERBB2 mutation achieved clinical benefit.
Hypothesizing that tumours with an increased tumour mutational burden (TMB) might be more likely to acquire HER2 mutations without developing oncogenic dependence (that is, passenger mutations), we evaluated whether overall TMB status affected outcome. Using a previously validated cut-off (≥ 13.8 non-synonymous mutations per megabase of DNA 2 ), 20% of patients (17 out of 86) met criteria for a high TMB. In total, 24% of patients (16 out of 66) without clinical benefit versus 5% of patients (1 out of 20) with benefit met criteria for a high TMB, a trend that did not reach statistical significance (P = 0.10).
Next, we evaluated whether the pattern of co-mutations affected clinical benefit in the subset of patients where broader profiling was available (n = 86). In patients with HER2-mutant disease, coincident mutations in TP53 and HER3 were enriched in patients with no clinical benefit (nominal P = 0.018 and P = 0.064, respectively; Fig. 3 ). Although not significant after correcting for multiple hypothesis testing, potentially owing to the relatively small sample size, it is noteworthy that no patients with clinical benefit possessed co-mutation of HER2 and HER3. Concurrent mutation of these genes was observed in multiple cancer types (breast n = 3, bladder n = 2, gastroesophageal n = 2, colorectal n = 1 and pancreatic n = 1) and involved a variety of unique HER2 and HER3 mutations (n = 8 and n = 9, respectively). Expanding our analysis to genomic activation at the pathway level, we identified somatic mutations of known oncogenic potential and grouped them by those involving the receptor tyrosine kinase (RTK)/RAS/RAF and PIK3CA/AKT/mTOR pathways, and cell cycle checkpoints (Extended Data Fig. 5b ). In this analysis, concurrent aberrations in cell cycle checkpoints were associated with lack of clinical benefit (P = 0.043), and activation of RTK/RAS/RAF also trended towards a worse outcome (P = 0.060). The association between the cell-cycle pathway and lack of clinical benefit seems to be primarily driven by TP53 mutations, losing significance upon removal of TP53 mutations (P = 0.769). Interestingly, activation of the PI3K/AKT/mTOR pathway, an established negative predictor of response to HER2-targeted therapy in HER2-amplified breast cancer [20] [21] [22] , did not adversely affect the likelihood of clinical benefit (P = 0.753). It is possible that the clinical impact of concurrent gene/pathway activation may vary by tumour type, and future disease-specific studies are needed to define these associations better. Although these were exploratory analyses that will require confirmation, our results suggest that concurrent activation of specific genes as well as pathways may act as an additional modifier of response beyond cancer type and specific HER2 mutant allele.
Discussion
The ability to profile cancer comprehensively at the point of care has made possible the opportunity to personalize therapy for each patient based on the compendium of genomic alterations identified 23 . Despite the promise of this approach, implementing this paradigm in clinical practice has been hampered by considerable gaps in knowledge about the biological and clinical importance of most genomic variants identified 24 . This challenge is exemplified by the marked diversity and wide distribution of HER2 and HER3 mutations in human cancers, as well as by the difficulty of generating preclinical models of these mutations that correctly recreate their biology in patients. To our knowledge, SUMMIT provides the first comprehensive dataset on the clinical actionability of HER2 and HER3 mutations. We found that HER2 mutations are associated with HER2-dependence in a subset of patients with HER2-mutant tumours, but that response to HER kinase inhibition varies a function of the individual mutant variant, the tumour type as well as the pattern of co-mutations present. Although we identified promising preliminary activity for neratinib in breast, biliary and cervical cancers, the response rate in these tumours was still lower than with approved therapies that target oncogenic alterations in EGFR, ALK, ROS1 and BRAF. The low response rate in lung cancer, in which HER2 mutations exhibit mutually exclusivity with other known drivers 25 , is also notable and may in part reflect a lower potency of neratinib inhibition in Y772_A775dup compared to other insertions or missense mutants 18 . Successfully targeting HER2 activation in other contexts has historically necessitated drug combinations. For example, single-agent trastuzumab has a response rate of only approximately 20% in ERBB2-amplified breast cancer 26, 27 . By contrast, the overall survival in ERBB2-amplified breast and gastroesophageal cancers is markedly improved by adding trastuzumab to chemotherapy 28, 29 . More recently, the intensification of HER2 inhibition through the combination of two HER2-targeted agents has been shown to result in synergistic efficacy in patients with ERBB2-amplified breast [30] [31] [32] or colorectal 33, 34 cancers, as well as in HER2-mutant colorectal cancer xenografts 6 . Cumulatively, these data suggest that combining neratinib with another HER2-targeted therapy is a rational next step, and SUMMIT has been amended to evaluate this approach in multiple HER2-mutant tumour types.
SUMMIT represents a continued evolution in the design of basket studies, which enrol patients on the basis of qualifying mutations rather than tumour type. The initial generation of these studies focused on evaluating individual somatic mutations that were already clinically validated in one cancer (such as BRAF V600 in melanoma) in other tumour types 10, 35 . More recently, basket studies have been used to generate initial or even practice-changing clinical data of truly novel genomic biomarkers, especially when these genomic alterations occur at low frequency across a wide distribution of cancer types 11, 36, 37 . SUMMIT extends this concept one step further by demonstrating for the first time how a single study can be used to simultaneously evaluate a range of individual variants in HER2 and HER3, each with varying degrees of prior biologic characterization. This permissive enrolment strategy allowed us to treat patients harbouring mutations that, at the time of enrolment, had not been characterized preclinically as gain-offunction but were either recurrent or paralogous to known activating mutations in homologous genes. For example, patients with previously uncharacterized HER2 variants, such as V697L, D769N/H/Y and L869R, were included in this manner and responded to treatment, thus providing initial clinical proof-of-concept that these mutations confer a gain-of-function phenotype even before formal biologic characterization. The approach of pairing a permissive enrolment strategy with allele prioritization based on recurrence, paralogy and other readily computable features has potentially broad applicability to implementing genomic-driven oncology 24 . This strategy will take on even greater importance as clinical testing moves from targeted sequencing to whole exome or even whole genome sequencing, techniques that will allow for evaluation of an even greater number of therapeutic hypothesis but will also exponentially expand the number of uncharacterized alleles we routinely identify.
SUMMIT provides additional insights into the conduct of molecularly driven oncology studies. Our ability to understand the complex interactions between tumour lineage, individual HER2 variant and response to neratinib was only possible because of the relatively large size of this study (n = 141). By comparison, many of the 'master/ umbrella' protocols that are currently underway are designed to enrol a maximum of 30-40 patients into each genomically defined treatment arm. Our experience suggests that many studies of this size may be inadequately powered to identify the subgroups with true efficacy, assuming that most genomic alterations will not predict for tumourtype agnostic efficacy. SUMMIT also demonstrates the feasibility of enrolling patients based on local testing, with patients treated on the basis of 30 unique sequencing assays performed in 25 different laboratories. Despite this, concordance on retrospective central review was extremely high (96%).
An important impediment to progress in oncology has been the limited availability of preclinical model systems that accurately recreate the complex biology of human cancer. Although important strides have been made, the wide-scale profiling of cancer in the clinic provides the potentially transformative opportunity to interrogate cancer biology at the bedside in a manner previously only possible at the bench. Here, we demonstrate how this opportunity can be leveraged to probe the biology of a diverse set of HER2 and HER3 mutations across a variety of solid tumours through pharmacological HER kinase inhibition in patients. In doing so, we found that response to pharmacological inhibition was based on the characteristics of both tumour type and genomic variant to a degree that was not predicted by established preclinical models. In summary, SUMMIT demonstrates how the clinical trial can become an important tool in refining our understanding of the biological dependencies in human cancers.
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Extended Data 
Data exclusions
Describe any data exclusions. The clinical data presented represent an intention to treat population with all patients who received at least one dose of neratinib included in analysis. The genomic data presented include all samples that underwent sequencing and passed routine QA/QC procedures as described and referenced.
Replication
Describe whether the experimental findings were reliably reproduced.
As this is a clinical trial, no replication was possible or performed.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
There was no randomization.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
This was an open label study with no blinding.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). No animals were used
